TMEM37 and acute myeloid leukemia: Sergeeva et al. reported the development of a TCR-like murine IgG2a mAb, m84, which binds to PR1/HLA-A2+ AML, mediating the lysis of AML in vivo, which successfully depleted AML in vitro [76,77].